31results about How to "Poor response" patented technology

A system and method of tagging utterances with Named Entity Recognition (“NER”) labels using unmanaged crowds is provided. The system may generate various annotation jobs in which a user, among a crowd, is asked to tag which parts of an utterance, if any, relate to various entities associated with a domain. For a given domain that is associated with a number of entities that exceeds a threshold N value, multiple batches of jobs (each batch having jobs that have a limited number of entities for tagging) may be used to tag a given utterance from that domain. This reduces the cognitive load imposed on a user, and prevents the user from having to tag more than N entities. As such, a domain with a large number of entities may be tagged efficiently by crowd participants without overloading each crowd participant with too many entities to tag.

Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions thereof, strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.

Methods and systems for extruding polymeric fibers are disclosed. The extrusion process preferably involves the delivery of a lubricant separately from a polymer melt stream to each orifice of an extrusion die such that the lubricant preferably encases the polymer melt stream as it passes through the die orifice.

The invention has: a housing; a pump section formed of a drive gear unit and a driven gear unit; a main flow channel through which oil pressure is applied to the driven gear unit in a discharge volume reduction direction; a first branching flow channel through which oil pressure that assists oil pressure from the main flow channel is applied; a second branching flow channel through which oil pressure is applied to the driven gear unit in a discharge increase direction; a first flow channel control section; a second flow channel control section; and a spring that elastically urges the driven gear unit in a discharge increase direction. The first flow channel control section and the second flow channel control section can perform switching control in accordance with each increase or decrease of engine revolutions and in pressure.

A method for testing a liquid crystal display panel wherein there are, disposed in matrix form, pixels comprising liquid crystal elements in which a liquid crystal material is sealed between opposing electrodes, this method for testing a liquid crystal display panel being characterized in that it comprises a first charging step for applying a first voltage between the opposing electrodes of the liquid crystal element of the pixel under test; a second charging step for applying a second voltage of the opposite polarity of the first voltage between the opposing electrodes of the liquid crystal element of the pixel under test; and a measuring step for discharging the charge that has accumulated in the electrodes of the liquid crystal element of the pixel under test after the second charging step, and measuring the amount of charge discharged.

A signal processing apparatus includes: a connecting means for use in connecting to a different device; a signal control means for changing a control signal to be outputted to the different device through the connecting means for a predetermined period; a changing means for changing the predetermined period; a determining means for determining for each of the predetermined periods changed by the changing means whether the different device stably makes a response to a change in the control signal caused by the signal control means; and a deciding means for deciding a shortest predetermined period from the predetermined periods determined by the determining means that the different device stably makes a response, as a standby time for the different device connected through the connecting means.

The invention relates to a method for preparing aryl trifluoroethoxyl ether. The method includes the steps that aryl boron compounds and trifluoroethanol are added to organic solvent, a copper salt catalyst, a ligand and an oxidizing agent are added, a reaction is conducted in a stirring mode for 1-40 hours at the temperature of 0-60 DEG C, filtering is conducted, column chromatography isolation is conducted, and the aryl trifluoroethoxyl ether is obtained. The method is simple in operation, raw materials are easy to obtain, the reaction condition is mild, the substrate universality is wide, the environmental friendliness is achieved, and the method is applicable to industrial application.

Described are methods for inducing an immune response in a subject against an antigen from a malaria-causing parasite, preferably P. falciparum, the method comprising: (i) administering to a subject a priming composition comprising adjuvanted proteinaceous antigen-comprising circumsporozoite (CS) protein or an immunogenic part thereof from a malaria-causing parasite; (ii) administering to the subject a first boosting composition comprising a recombinant adenovirus vector that comprises nucleic acid encoding CS protein or immunogenic part thereof from a malaria-causing parasite; and (iii) administering to the subject a second boosting composition comprising a recombinant adenovirus vector that comprises nucleic acid encoding CS protein or an immunogenic part thereof from a malaria-causing parasite, wherein either the first boosting composition comprises a recombinant adenovirus vector of serotype 35 (Ad35) and the second boosting composition comprises a recombinant adenovirus of Ad26, or wherein the first boosting composition comprises a recombinant adenovirus vector of Ad26 and the second boosting composition comprises a recombinant adenovirus of Ad35.

The disclosure describes amphiphilic ligand conjugates comprising a chimeric antigen receptor (CAR) ligand, a lipid (diacyl lipid), a linker (hydrophilic polymers, hydrophilic amino acids, polysaccharides), compositions and methods of using the constructs are claimed, for example, to stimulate proliferation of CAR expressing cells.

The invention relates to a synthetic method of an A-D-A organic photoelectric micro-molecule based on perylene diimide and pentacene. The synthetic method includes the steps: dissolving 6, 13-bi (triisopropyl silicon acetenyl) pentacene-2, 9-bi-pinacol ester or 6, 13-bi (triisopropyl silicon acetenyl) pentacene-2, 10-bi-pinacol ester and 1-bromine perylene diimide in solvents under inert atmosphere; performing coupled reaction under the action of catalysts to obtain 2, 10-biperylene diimide-6, 13-bi (triisopropyl silicon acetenyl) pentacene or 2, 9-biperylene diimide-6, 13-bi (triisopropyl silicon acetenyl) pentacene; performing LED (light-emitting diode) lamp illumination and photocycloaddition reaction under the action of iodine elementary substances to prepare the micro-molecule. According to the method, electron acceptor materials with excellent performances and singlet-state fission model molecules are firstly assembled into one molecule, and the molecule is applied to fields suchas organic solar cells, field effect transistors, photoelectric detectors and organic light emitting diodes.

An exposure apparatus includes an optical system for guiding light to an object, a holding member for holding the object, a first refrigerator located near a holding side of the holding member without contacting the holding side, and a second refrigerator located near a backside of the holding member without contacting the backside.

An intervention for sleep disorders comprises: collagen, a gelatin peptide, or the amino acid glycine; L-theanine; lactucopicrin, deoxylactucopicrin, or another lactucopicrin derivative; hyaluronic acid; epigallocatechin gallate; and quinic acid. The intervention helps regulate pro-inflammatory biomarkers that are often associated with insomnia development and progression. These biomarkers include cytokines and enzymes associated with tryptophan degradation. Inhibition of these enzymes and cytokines improves tryptophan availability and sleep quality, and allows individuals to sleep better with fewer side effects. The composition promotes high-quality, deep sleep.

The invention relates to the field of organic synthesis, in particular to a production process of evodiamine and a method for recycling a solvent in production. According to the method, tryptamine isadopted as a raw material, evodiamine is obtained through formylation, cyclization and condensation ring closing, phosgene and ethyl chloroformate are prevented from being used in the whole process, the safety risk in the production process is reduced, and the reaction steps are greatly simplified. Meanwhile, a solvent application process in production is realized, so that the production cost is greatly reduced, and the method has an industrial popularization value.

The present invention provides a method for predicting the treatment response to anti-cancer immunotherapy of a mammalian cancer patient, the method comprising: a) measuring the gene expression of at least 2 the following cancer promoting genes: PTGS2, VEGFA, CCL2, IL8, CXCL2, CXCL1, CSF3, IL6, IL1B and IL A in a sample obtained from the tumour of the patient; b) measuring the gene expression of at least 2 of the following cancer inhibitory genes: CXCL11, CXCL10, CXCL9, CCL5, TBX21, EOMES, CD8B, CD8A, PRF1, GZMB, GZMA, STAT1, IFNG, IL12B and IL12A in a sample obtained from the tumour of the patient; c) computing a ratio of the gene expression of said at least 2 cancer promoting genes and the gene expression of said at least 2 cancer inhibitory genes; and d) making a prediction of the treatment response and / or prognosis of the patient based on the gene expression ratio computed in step c). Also provided are related methods for stratifying patients and for treating patients, including with immune checkpoint blockade therapy.

The invention discloses a micro-fluidic chip device for biogenic amine detection and application. The micro-fluidic chip device comprises a sample inlet, a connecting channel, a detection module and an air pressure driving area; the sample inlet, the detection module and the air pressure driving area are sequentially connected through the connecting channel; the sample inlet is connected with the atmosphere; the detection module comprises a cellulose acetate-based fluorescent substance modified three-dimensional porous polydimethylsiloxane (PDMS) structure, and the air pressure driving area provides negative pressure in a pressing mode to promote to-be-detected gas or liquid outside the chip to enter the chip. The food freshness can be judged by detecting the response conditions of biogenic amines in different foods. The prepared micro-fluidic device has quick and reversible response to biogenic amine, so that the micro-fluidic device can be easily used as a quick detection device and can be practically applied to the food industry.

A novel and improved vaccine for prevention of disease caused by the Severe Acute Respiratory Syndrome-2 (SARS-2), / COVID-19 virus. Current mRNA and Adenovirus vaccine technologies for SARS-2 provide high levels of serum Immunoglobin G (IgG), antibodies against the original Wuhan strain, but there are now hundreds of mutant strains which can evade both vaccine and convalescent antibodies. These vaccines also do not provide strong mucosal IgA class antibodies which provide wider protection against mutant strains of Flu A and other respiratory viruses. The ability of these technologies to provide high levels of protection is in question, as serum neutralizing antibodies may decline to undetectable levels after six months. The appearance of mutant strains such as the Beta, Gamma, Delta, and Epsilon strains, containing altered amino acid sequences capable of evading vaccine-induced antibodies, calls for new vaccine technologies that can be quickly altered to meet this threat. The following describes a combination approach to prevention of infection by SARS-2 / COVID-19. This combination consists of a priming injection of Recombinant Replicative Particles (VRP) derived from the Alphavirus Venezuelan Equine Encephalitis (VEE) strain 3000 / 3526, with insertion of a Delta / B.1.617.2 SARS-2 / COVID-19 spike 1 glycoprotein (gp)-Receptor-Binding Domain (RBD) gene. The insertion of Internal Ribosome Entry Sites (IRES), elements between the 26S promoter and the SARS-2 / COVID RBD gene allows for more efficient translation of the SARS-2 / COVID gene products. The VEE3000 / 3256 VRP are produced from plasmids, so while they are infectious for one replicative cycle in vivo, progeny VRP are replication incompetent. The priming is followed by one or more intranasal administrations of a suspension of recombinant SARS-2 / COVID-19 envelope spike 1 glycoproteins (gp), from selected mutant strains, combined with the pulmonary surfactant adjuvant, SF-10. The goal of the invention is to safely provide multiple immune layers of protection in both the upper and lower respiratory tracts, with induction of both mucosal IgA and serum IgG antibodies, as well as effector Cytotoxic T Lymphocyte (CTL), cells recognizing conserved regions of the SARS-2 / COVID-19 virus genome. Secondary goals are to reduce the risk of antibody-dependent enhancement (ADE), of infection, a major concern with other SARS-2 / COVID-19 vaccine designs, and to provide capacity to protect against mutant emergent strains of SARS-2 / COVID-19 with annual intranasal boosters of new spike glycoproteins.

Prognostic method in colorectal cancer based on the determination of the expression levels of the EphB4 gene in tumours of patients afflicted by this disease. The levels can be used as a marker for the probability of the recurrence of the cancer in the patient and for the prognostics of the sensitivity that the tumours present to treatment with 5-fluorouracil, allowing to establish the more adequate therapeutic strategy for every patient.

The invention discloses a preparation method of medical ultra-high molecular weight poly (p-dioxanone). The preparation method comprises the following steps: 1) purifying p-dioxanone; 2) polymerization reaction: heating a reaction kettle, filling inert gas into the reaction kettle, adding the purified p-dioxanone prepared in the step 1), and adding a catalyst and an alcohol initiator for reaction; (3) after the reaction is finished, taking out the materials and crushing the materials; and 4) heating the crushed material under a vacuum condition to remove unreacted p-dioxanone, and finally preparing the poly (p-dioxanone). The high-molecular-weight poly (p-dioxanone) prepared by the preparation method can meet medical requirements, the molecular weight can reach 300000 to 2000000, and the production magnitude can reach dozens of kilograms by using a catalyst stannous octoate accepted by FDA (Food and Drug Administration).

The present invention provides, for the first time, the finding that the manganese superoxide dismutase Val16Ala polymorphism is significantly associated with prognosis for cancer patients treated with chemotherapeutic drug therapy. The alanine allele is a novel biomarker that predicts poor response and poor outcome to chemotherapeutic drug cancer therapy. Conversely, the valine allele predicts a good response and a good outcome to chemotherapeutic drug cancer therapy. Therefore, a genotype assay can be used to determine which alleles a subject is carrying, and subsequently this information can be used to determine if chemotherapeutic drug therapy is appropriate, and to customize therapy according to the patient's MnSOD genotype.